How it Works
Tell us what you need by filling in the form
Receive Verified supplier details
Compare Quotations and seal the deal
X
I agree to the terms and privacy policy
144188195215245280

Datar Genetics Limited

Nashik, Maharashtra

| Verified Supplier

View Mobile Number

Datar Genetics Limited - Service Provider of liquid biopsy, liquid biopsy for brain tumor & tumor tissue analysis in Nashik, Maharashtra.

Liquid Biopsy

Liquid Biopsy

Get Quote

Liquid Biopsy
Get Best Quote

Liquid Biopsy

Get Latest Price

Cancertrack offers patients a non-invasive blood test that detects cancer cells and their fragments with ultra-high precision, specificity and reliability. The test lets Doctors check for cancerous cell / cancer cell fragments to monitor recurrence of the disease or keeping an eye on changes in the tumor characteristics, as often as necessary, without the risk of radiation from scans, hospitalization, anesthesia or painful surgical biopsies.

Cancertrack utilizes multi co-ordinate and multi-dimensional probes to hunt down the tiniest of fragments of cells / DNA / RNA released by cancer cells in the patient’s blood.

Cancertrack is an ultra precision Liquid Biopsy based on gene interrogation for all types of cancers.It can eliminate the need for repetitive costly / inaccessible / painful biopsies and is an excellent and reliable test to determine the presence / recurrence / therapy response of malignancy in suspected or under treatment cancer patients.

Cancertrack gives unprecedented capability to detect cancerous activity which is otherwise impossible to scan or search through conventional techniques like PET-CT / MRI / Ultrasound etc.

Cancertrack is suitable for
  • Every cancer patient.
  • Every patient who is under treatment for cancer.
  • Every patient who is in remission / cancer survivor and needs monitoring.
  • Every patient in whom the cancer is not responding satisfactorily to therapy.
  • Every asymptomatic person who has a high risk profile after genetic analysis / strong family history and periodic screening is recommended.

View Complete Details

Yes I'm interested

Liquid Biopsy For Brain Tumor
Get Best Quote

Gliotrack™ detects tumor biomarkers like cell free tumor DNA (ctDNA), mRNA and microRNA released by the tumor cells in peripheral blood of the patient. Cell free tumor DNA (ctDNA) is released by the dying tumor cells whereas mRNA and microRNA are actively secreted in the form of exosomes by the live tumor cells.

Several circulating biomarkers in the peripheral blood such as circulating tumor cells, tumor derived cell free DNA (ctDNA), tumor derived micro-vesicles called exosomes are considered in recent years for their use in non-invasive assessment of tumor derived molecular artifacts due to their high sensitivity and specificity. The analysis of circulating, cell free DNA is one of the most promising technical advances to provide an alternative to tumor biopsy.

Cell-free DNA released by the tumor contains all variants present in the tumor, allowing precise non-invasive monitoring of cancer in real time. These biomarkers together represent the complete tumor activity. Detection of these biomarkers from peripheral blood overcomes the issue of molecular heterogeneity of tumor.

Gliotrack™ is suitable for
  • Patients with suspected glioma on MRI.
  • Patients with glioma who are unfit for biopsy e.g. Diffuse intrinsic pontine glioma or associated comorbidities.
  • Patients with inadequate tissue sample for molecular stratification /  prognostication.
  • Diagnosed glioma patients – to select optimum therapy or to monitor therapy response .
  • Patients on treatment – to distinguish true disease progression from treatment associated changes like radiation necrosis and to monitor residual disease.
  • Patients in remission – to detect recurrence at the earliest.

View Complete Details

Yes I'm interested

Tumor Tissue Analysis
Get Best Quote

Tumor Tissue Analysis

Get Latest Price

Cancer is a disease of the genes. Like every human being, each person’s cancer is unique. Unfortunately, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient’s tumor and consequently patients usually suffer due to failed therapies or aggressive relapse. It is thus imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan.Exacta is useful for cancer patients where
  • First Line Therapy has failed
  • Cancer has relapsed
  • Cancer is High Grade / Metastatic
  • Risk of Therapy Failure is highExacta unravels the deepest genetic secrets of an individual patient’s cancer by accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome. Exacta reaches the depths of cancer’s mechanisms through 100s of millions of data points. This reveals the driver mutations and pathways that are propelling a particular person’s cancer and can be targeted with precision drugs. Exacta thus enables a highly sophisticated treatment strategy beyond conventional perspective. This is the unmatched strength of Exacta. Exacta is the latest and world’s best molecular analysis for difficult cancers. Consider ScreenGeneTM in Patient / Proband with :
    • Cancer at early age e.g. Breast / Ovary / Endometrial / Colorectal at age 50 or younger.
    • Two or more different types of cancer.
    • Cancer in both organs in a set of paired organs e.g. Bilateral Breast cancer.
    • Unusual presentation of cancer e.g. Breast cancer in a Male.
    • Cancer with specific features e.g. Triple negative breast cancer, MSI high colon cancer.
    • Cancer under treatment to identify therapy relevant hereditary gene mutations e.g. BRCA and PARP inhibitors.

View Complete Details

Yes I'm interested

Screening For Hereditary Cancers
Get Best Quote

Hereditary Cancer Syndromes can be caused by faulty changes in genes called as “Hereditary Mutations.” These can be passed down from parent to child and cause cancer to run in the family, making it a Hereditary Cancer. Women who carry a mutation in either of BRCA genes have a condition called Hereditary Breast Ovarian Cancers (HBOC) syndrome. Approximately 10-15 percent of Ovarian cancer cases and 10 percent of Breast cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. Some more genes have also been found to be responsible for Hereditary Breast or Ovarian Cancer. In addition, mutation carriers who have already been diagnosed with cancer have a significantly increased risk of developing a second cancer in the future.

Lynch Syndrome is also called Hereditary Non Polyposis Colon Cancer (HNPCC). It caused by mutations in the MLH1, MSH2, MSH6 , PMS2 or EPCAM genes.

Out of 10 people with Lynch syndrome, between 7 to 9 people develop bowel cancer. People with Lynch syndrome are at higher risk of developing cancers like Colorectal cancer, Uterine (endometrial) cancer, Ovarian cancer and Gastric (stomach) cancer. Many other cancers like Melanoma, Retinoblastoma, Wilm’s tumor etc. have been established to have hereditary association.

View Complete Details

Yes I'm interested

Liquid Biopsy

Get Latest Price

Cancertrack offers patients a non-invasive blood test that detects cancer cells and their fragments with ultra-high precision, specificity and reliability. The test lets Doctors check for cancerous cell / cancer cell fragments to monitor recurrence of the disease or keeping an eye on changes in the tumor characteristics, as often as necessary, without the risk of radiation from scans, hospitalization, anesthesia or painful surgical biopsies.

Cancertrack utilizes multi co-ordinate and multi-dimensional probes to hunt down the tiniest of fragments of cells / DNA / RNA released by cancer cells in the patient’s blood.

Cancertrack is an ultra precision Liquid Biopsy based on gene interrogation for all types of cancers.It can eliminate the need for repetitive costly / inaccessible / painful biopsies and is an excellent and reliable test to determine the presence / recurrence / therapy response of malignancy in suspected or under treatment cancer patients.

Cancertrack gives unprecedented capability to detect cancerous activity which is otherwise impossible to scan or search through conventional techniques like PET-CT / MRI / Ultrasound etc.

Cancertrack is suitable for
  • Every cancer patient.
  • Every patient who is under treatment for cancer.
  • Every patient who is in remission / cancer survivor and needs monitoring.
  • Every patient in whom the cancer is not responding satisfactorily to therapy.
  • Every asymptomatic person who has a high risk profile after genetic analysis / strong family history and periodic screening is recommended.

View Complete Details

Get Best Quote
Yes I'm interested

Gliotrack™ detects tumor biomarkers like cell free tumor DNA (ctDNA), mRNA and microRNA released by the tumor cells in peripheral blood of the patient. Cell free tumor DNA (ctDNA) is released by the dying tumor cells whereas mRNA and microRNA are actively secreted in the form of exosomes by the live tumor cells.

Several circulating biomarkers in the peripheral blood such as circulating tumor cells, tumor derived cell free DNA (ctDNA), tumor derived micro-vesicles called exosomes are considered in recent years for their use in non-invasive assessment of tumor derived molecular artifacts due to their high sensitivity and specificity. The analysis of circulating, cell free DNA is one of the most promising technical advances to provide an alternative to tumor biopsy.

Cell-free DNA released by the tumor contains all variants present in the tumor, allowing precise non-invasive monitoring of cancer in real time. These biomarkers together represent the complete tumor activity. Detection of these biomarkers from peripheral blood overcomes the issue of molecular heterogeneity of tumor.

Gliotrack™ is suitable for
  • Patients with suspected glioma on MRI.
  • Patients with glioma who are unfit for biopsy e.g. Diffuse intrinsic pontine glioma or associated comorbidities.
  • Patients with inadequate tissue sample for molecular stratification /  prognostication.
  • Diagnosed glioma patients – to select optimum therapy or to monitor therapy response .
  • Patients on treatment – to distinguish true disease progression from treatment associated changes like radiation necrosis and to monitor residual disease.
  • Patients in remission – to detect recurrence at the earliest.

View Complete Details

Get Best Quote
Yes I'm interested

Tumor Tissue Analysis

Get Latest Price

Cancer is a disease of the genes. Like every human being, each person’s cancer is unique. Unfortunately, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient’s tumor and consequently patients usually suffer due to failed therapies or aggressive relapse. It is thus imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan.

Exacta unravels the deepest genetic secrets of an individual patient’s cancer by accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome. Exacta reaches the depths of cancer’s mechanisms through 100s of millions of data points. This reveals the driver mutations and pathways that are propelling a particular person’s cancer and can be targeted with precision drugs. Exacta thus enables a highly sophisticated treatment strategy beyond conventional perspective. This is the unmatched strength of Exacta. Exacta is the latest and world’s best molecular analysis for difficult cancers.

Exacta is useful for cancer patients where
  • First Line Therapy has failed
  • Cancer has relapsed
  • Cancer is High Grade / Metastatic
  • Risk of Therapy Failure is high.

View Complete Details

Get Best Quote
Yes I'm interested

Chemo Sensitivity

Get Latest Price

Once diagnosed with cancer, routinely patient receives the “conventional / standard” chemotherapy regimens. These regimens are common to all patients with that particular cancer type. Such “one size fits all” approach is one of the most important reasons of treatment failure and cancer recurrence. Cancer is a disease which has unique properties and differs in every patient and hence every patient responds differently to same chemotherapy.

Few patients undergo remission whereas few have cancer progression even after receiving cancer treatment. And this cancer progression or failure of treatment becomes evident after many days of receiving the chemotherapy and after suffering all the side effects of the chemotherapy. Time is very precious for successful cancer management and this precious time is lost with the conventional “trial and error” approach. At the same time, precious financial resources are wasted in drugs which had no benefit and gave harsh side effects. Hence it is very beneficial for the patient and the treating physician, if it is already known which drugs will give maximum benefit in that individual patient’s tumor.

Correkt-chemo directly tests the effect of chemotherapy / anti- cancer drugs on the patient’s tumor cells. It helps to customize your treatment plan according to sensitivity and resistance pattern of your tumor cells. When armed with this information, your physician and you can ensure that you receive the most effective chemotherapy from all available options.

This personalization of your chemotherapy by directly studying effect of chemotherapy drugs on cells taken from fresh biopsy sample of your tumor – is the Correkt-chemo test. In this test, fresh tumor cells obtained by biopsy / surgery are treated with different chemotherapy drugs. The effect of drug is measured directly by its ability to kill the tumor cells. Consequent upon this information, the drugs are listed in their order of comparative efficacy to kill the tumor cells.

Correkt-chemo is suitable for
  • Every cancer patient with or without metastasis, before starting cancer treatment.
  • Every patient who is under treatment for cancer.
  • Every patient in whom the cancer is not responding satisfactorily to therapy.

View Complete Details

Get Best Quote
Yes I'm interested

Get Price & Details

Get Price & Details

Get Price & Details

About Us

Datar Genetics Limited - Service Provider of liquid biopsy, liquid biopsy for brain tumor & tumor tissue analysis in Nashik, Maharashtra.

Download Brochure

Nature of Business

Service Provider

Legal Status of Firm

Private Limited Company
Send us a Quick Message!
Tell Us What Are You Looking For?
I agree to the terms and privacy policy
View Mobile Number  to reach us quickly
Tell us what you
need
Receive seller
details
Seal the deal
Save time! Get Best Deal
I agree to the terms and privacy policy